Phase II study of the combination of Eribulin and Trastuzumab Evaluating Efficacy and Safety in Patients with advanced/recurrent HER2-positive breast cancer.
Phase of Trial: Phase II
Latest Information Update: 12 May 2016
At a glance
- Drugs Eribulin (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 04 Jul 2013 New trial record